Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trial

Autor: Wu, Chun-Ying, Lee, Yi-Chia, Tseng, Ping-Huei, Wu, Jeng-Yih, Tai, Chi-Ming, Lee, Ching-Tai, Wang, Wen-Lun, Liou, Jyh-Ming *, *, Jiang, Xiao-Tao *, Chen, Chieh-Chang, Luo, Jiing-Chyuan, Bair, Ming-Jong, Chen, Po-Yueh, Chou, Chu-Kuang, Fang, Yu-Jen, Chen, Mei-Jyh, Chen, Chien-Chuan, Lee, Ji-Yuh, Yang, Tsung-Hua, Yu, Chien-Chun, Kuo, Chia-Chi, Chiu, Min-Chin, Chen, Chi-Yi, Shun, Chia-Tung, Hu, Wen-Hao, Tsai, Min-Horn, Hsu, Yao-Chun, Tseng, Cheng-Hao, Chang, Chi-Yang, Lin, Jaw-Town, El-Omar, Emad M, Wu, Ming-Shiang
Zdroj: In The Lancet Gastroenterology & Hepatology March 2023 8(3):228-241
Databáze: ScienceDirect